Quick Answer
PDS Biotechnology Corp reported Net Income of -$34.50 million for fiscal year 2025.
PDS Biotechnology Corp — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$34.50M +8.3% |
-$37.61M +12.4% |
-$42.94M -5.1% |
-$40.85M -141.5% |
-$16.92M -13.9% |
-$14.85M -112.1% |
| Diluted EPS | -$0.74 +28.2% |
-$1.03 +25.9% |
-$1.39 +2.8% |
-$1.43 -116.7% |
-$0.66 +25.8% |
-$0.89 |
| Total Assets | $30.49M -32.8% |
$45.36M -23.6% |
$59.39M -22.9% |
$77.01M +14.6% |
$67.20M +117.5% |
$30.89M +113.2% |
| Cash and Equivalents | $26.71M -35.9% |
$41.69M -26.3% |
$56.56M -23.4% |
$73.82M +13.1% |
$65.24M +126.2% |
$28.84M +137.1% |
| Stockholders Equity | $22.36M -39.9% |
$37.18M -9.3% |
$41.01M -20.3% |
$51.43M | — | — |
| R&D Expense | $19.03M -15.7% |
$22.57M -18.7% |
$27.76M -5.7% |
$29.43M +161.5% |
$11.25M +42.0% |
$7.92M +29.9% |
| Operating Income | -$31.54M +13.2% |
-$36.32M +15.6% |
-$43.05M -3.3% |
-$41.67M -94.4% |
-$21.44M -43.9% |
-$14.90M +29.2% |
| Shares Outstanding | 54.88M +44.5% |
37.99M +14.8% |
33.09M +9.7% |
30.17M +6.1% |
28.45M +27.8% |
22.26M +321.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$9.01M | +16.0% | +4.5% |
| Diluted EPS | September 30, 2025 | -$0.19 | +34.5% | +9.5% |
| Total Assets | September 30, 2025 | $34.71M | -33.8% | -14.3% |
| Cash and Equivalents | September 30, 2025 | $26.20M | -47.3% | -17.8% |
| Stockholders Equity | September 30, 2025 | $9.45M | -57.0% | -40.8% |
| R&D Expense | September 30, 2025 | $4.58M | -32.7% | +8.6% |
| Operating Income | September 30, 2025 | -$8.14M | +20.0% | -6.8% |
| Shares Outstanding | September 30, 2025 | 47.71M | +29.6% | +2.3% |
- PDS Biotechnology Corp reported Net Income of -$34.50 million for fiscal year 2025.
- PDS Biotechnology Corp showed an increase of +8.3% in Net Income compared to the prior fiscal year.
- PDS Biotechnology Corp reported Diluted EPS of $0.74 per share (loss) for fiscal year 2025.
- PDS Biotechnology Corp showed an increase of +28.2% in Diluted EPS compared to the prior fiscal year.
- PDS Biotechnology Corp reported Total Assets of $30.49 million for fiscal year 2025.
- PDS Biotechnology Corp showed a decrease of -32.8% in Total Assets compared to the prior fiscal year.
- PDS Biotechnology Corp reported Cash and Equivalents of $26.71 million for fiscal year 2025.
- PDS Biotechnology Corp showed a decrease of -35.9% in Cash and Equivalents compared to the prior fiscal year.
- PDS Biotechnology Corp reported Stockholders Equity of $9.25 million for fiscal year 2025.
- PDS Biotechnology Corp showed a decrease of -2.1% in Stockholders Equity compared to the prior fiscal year.
- PDS Biotechnology Corp reported R&D Expense of $19.03 million for fiscal year 2025.
- PDS Biotechnology Corp showed a decrease of -15.7% in R&D Expense compared to the prior fiscal year.
- PDS Biotechnology Corp reported Operating Income of -$31.54 million for fiscal year 2025.
- PDS Biotechnology Corp showed an increase of +13.2% in Operating Income compared to the prior fiscal year.
- PDS Biotechnology Corp reported Shares Outstanding of 54.88 million shares for fiscal year 2025.
- PDS Biotechnology Corp showed an increase of +44.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: